# Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections)

> **NCT01599806** · PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 641 (actual)

## Conditions studied

- Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis

## Interventions

- **DRUG:** Ceftazidime - Avibactam ( CAZ-AVI)
- **DRUG:** Doripenem
- **DRUG:** Either switch to oral therapy: 500 mg of Ciprofloxacin (oral)
- **DRUG:** or switch to oral therapy: 800 mg/160 mg of sulfamethoxazole/trimethoprim (oral)

## Key facts

- **NCT ID:** NCT01599806
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-10
- **Primary completion:** 2014-08
- **Final completion:** 2014-08
- **Target enrollment:** 641 (ACTUAL)
- **Last updated:** 2017-09-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01599806

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01599806, "Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01599806. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*